Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.
R Donald HarveyNoemi Reguart AransayNicolas IsambertJong-Seok LeeTobias ArkenauJohan VansteenkistePaul A DickinsonKhanh BuiDoris WeilertKaren SoKaren ThomasKarthick VishwanathanPublished in: British journal of clinical pharmacology (2018)
Osimertinib is unlikely to have any clinically relevant interaction with CYP3A substrates and has a weak inhibitory effect on BCRP. No new safety concerns were identified in either study.